RAC 2.23% $1.75 race oncology ltd

Cardioprotection thread, page-377

  1. 918 Posts.
    lightbulb Created with Sketch. 10439
    Cardioprotection MoA - Calcium homeostasis

    I think that the MoA for cardioprotection is going to be around the regulation of caclium (Ca2+) in cardiomyocytes - potentially the RyR2, SERCA2, CaMKII, NF-kB, and p53 gene networks. Calcium homeostasis is dysregulated in both Anthracycline and Proteasome Inhibitor dosing.

    https://hotcopper.com.au/data/attachments/6087/6087078-93472c58cd7b832de577d6291cc7ba46.jpg

    High FTO activity in cardiomyocytes improves calcium handling, while FTO knockdown models demonstrated irregular heartbeats. This may indicate why the FTO inhibitors (brequinar, FB23-2, and Dac51) show a steady decrease in cell viability (increase in cardiomyocyte death) as dose concentration increases (below) - observe the red line on each chart. It could also just be because of increased toxicity generally. A cell model does not provide enough detail to truly understand the relationship between pharmacology and biology of a dynamic organ.

    https://hotcopper.com.au/data/attachments/6087/6087031-8ab5d234eb4a42325f7f652f48b2b9f9.jpghttps://hotcopper.com.au/data/attachments/6087/6087042-2b925a0a444eceb2d28bd61b96d47469.jpg

    Bisantrene clearly demonstrates improved cardioprotection, while also inhibiting FTO at significantly lower concentrations than the other molecules. I notice a dip in cell viability at the start, which starts to change around 250nM. If my wild speculation is correct, then this could be a sign of Bisantrene being counterproductive at lower concentrations (or just not working as a cardioprotective agent) where it is only inhibiting FTO, and when the cardioprotective concentrations are reached for the MoA, it begins positively influencing calcium homeostasis and providing cardioprotection.

    https://hotcopper.com.au/data/attachments/6087/6087110-44c2c5ebbab189b9b7e7183ade138979.jpghttps://hotcopper.com.au/data/attachments/6087/6087120-ac92b15a59c64510980aeb8483f43667.jpg

    If calcium handling is the MoA for cardioprotection, there are a couple of takeaways:

    1. The cardioprotective MoA is enough to buffer the effects of FTO inhibition dysregulation of calcium handling (as well as anthracene) - indicating a significant strength of that pathway
    2. If it is not a single pathway, then Bisantrene may be targeting multiple pathways that provide cardioprotection - indicating a truly unique drug
    3. If either 1 or 2 are correct, Bisantrene will become very challenging to replace clinically and, of course, commercially

    This is highly speculative, but I thought I would put my thoughts up.

    @Boffin99 what were your thoughts?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.75
Change
-0.040(2.23%)
Mkt cap ! $297.9M
Open High Low Value Volume
$1.79 $1.79 $1.72 $146.2K 83.61K

Buyers (Bids)

No. Vol. Price($)
1 2901 $1.73
 

Sellers (Offers)

Price($) Vol. No.
$1.75 994 1
View Market Depth
Last trade - 16.10pm 17/06/2024 (20 minute delay) ?
Last
$1.74
  Change
-0.040 ( 1.51 %)
Open High Low Volume
$1.76 $1.77 $1.72 23546
Last updated 15.56pm 17/06/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.